Orphinic Scientific

Orphinic Scientific functions as a biotechnology company focused on developing a portfolio of innovative therapies, with a particular emphasis on orphan drugs. The company utilizes an integrated drug development and investment model, designed to identify and cultivate promising pharmaceutical assets. This systematic approach advances drug candidates from late preclinical research through Phase 1 clinical development, addressing specialized areas of high unmet medical need.

The company was co-founded by Wojciech Tomikowski, who previously served in leadership roles such as General Manager/CEO at Novartis, and Jaroslaw Leszczyszyn, formerly Deputy CEO and Co-Founder at EMC Medical Institute. Artur Plonowski also stands as a co-founder and Chief Medical Officer. Their foundational insight stemmed from a commitment to bringing novel treatments to market for rare diseases, leveraging their combined expertise in biopharmaceutical development and investment strategies.

Orphinic Scientific serves patients worldwide who are affected by orphan diseases, conditions often lacking adequate treatment options. The company's long-term vision is to establish itself as a prominent force in the specialized therapeutic landscape by consistently expanding its pipeline of advanced drug candidates. Ultimately, Orphinic Scientific aims to deliver transformative cures that significantly enhance the well-being of individuals living with rare conditions.